ABCC8 and pulmonary arterial hypertension: Its experimental use in association with SUR1 mutations in PAH, however, has provided proof of concept that the pharmacologic rescue of mutant SUR1 is plausible and that SUR1-containing KATP channels with PAH-associated mutations are a potential druggable target in PAH [12].